Keyword: McKesson

Here is some news of note for pharmaceutical manufacturing.

Amazon's plan to jump into drug sales has hit a snag, and the retail giant has reportedly put at least one plan on ice.

Drugmakers haven't been able to reach a settlement with the cities and counties suing them over the opioid epidemic.

Hundreds of cities and counties have sued to hold opioid makers accountable for the addiction epidemic. Now the feds are getting involved.

Facing a rash of lawsuits claiming aggressive opioid marketing led to a nationwide epidemic, Purdue Pharma is reportedly initiating settlement talks.

Investors are demanding change at top drug distributors after an investigation exposed lax controls and lots of Capitol Hill arm-twisting.

After years of going it alone in investigating opioid drugmakers, attorneys general across the U.S. are joining forces to drill into painkiller marketing practices.

The generics pricing hit that's slammed Teva shares over last week? The company knew it was coming—and stayed mum for five weeks.

McKesson reported lower Q1 earnings a day after shareholders rejected an executive compensation plan at the company’s annual meeting held near Dallas.

AmerisourceBergen said the industry can expect branded prices to continue to rise 7% to 9%, while generics prices will keep sliding, off 7% to 9%.